Skip to main content
main-content

Rheumatoid arthritis

Medications

10-01-2019 | Rheumatoid arthritis | News

Biologic combination therapy for RA may increase risk for side effects

Findings from a systematic review and meta-analysis suggest that rheumatoid arthritis patients who receive combination therapy with two biologic DMARDs are more likely to experience adverse events than those given one biologic.

Source:

Semin Arthritis Rheum 2018; doi:10.1016/j.semarthrit.2018.12.003

09-01-2019 | Rheumatoid arthritis | News

Serious infection risk similar among non-TNF inhibitor biologics in RA

Study findings do not support the use of one non-tumor necrosis factor inhibitor biologic DMARD over another when considering the risk for serious infection in patients with rheumatoid arthritis.

Source:

Ann Rhuem Dis 2018; doi:10.1136/annrheumdis-2018-214326

07-01-2019 | Rheumatoid arthritis | News

Abatacept associated with lower serious infection risk than TNF inhibitors

Rheumatoid arthritis patients who are treated with abatacept have a lower risk for hospitalization due to infection than those given tumor necrosis factor inhibitors, findings from a real-world study suggest.

Source:

Arthritis Care Res 2018; doi:10.1002/acr.23824

Serum calprotectin predicts relapse risk in TNFi-treated RA, PsA

Serum calprotectin levels independently predict relapse risk in tumor necrosis factor inhibitor-treated patients with rheumatoid arthritis or psoriatic arthritis who are in remission or have low disease activity, Spanish researchers report.

20-12-2018 | Rheumatoid arthritis | Highlight | News

Serum calprotectin predicts relapse risk in TNFi-treated RA, PsA

Serum calprotectin levels independently predict relapse risk in tumor necrosis factor inhibitor-treated patients with rheumatoid arthritis or psoriatic arthritis who are in remission or have low disease activity, Spanish researchers report.

Source:

Arthritis Res Ther 2018; doi:10.1186/s13075-018-1764-z

14-12-2018 | Rheumatoid arthritis | News

Support for abatacept–methotrexate combination therapy in RA patients

Adding abatacept to methotrexate improves disease activity and reduces structural progression among ACPA-positive rheumatoid arthritis patients with early erosion, Japanese researchers report.

Source:

RMD Open 2018; 4: e000813

06-12-2018 | Rheumatoid arthritis | News

Targeting B cells may delay RA development in those at risk

B-cell directed therapy with a single infusion of rituximab significantly delays the development of rheumatoid arthritis in people at high risk for developing the condition, exploratory study data show.

Source:

Ann Rheum Dis 2018; doi:10.1136/annrheumdis-2017-212763

Chronic opioid use rising in RA patients

Chronic opioid use among patients with rheumatoid arthritis increased substantially between 2002 and 2015, researchers report.

03-12-2018 | Rheumatoid arthritis | Highlight | News

Chronic opioid use rising in RA patients

Chronic opioid use among patients with rheumatoid arthritis increased substantially between 2002 and 2015, researchers report.

Source:

Arthritis Rheumatol 2018; doi:10.1002/art.40789

30-11-2018 | Rheumatoid arthritis | News

Biomarker score reflects rituximab response in RA patients

Changes in the multi-biomarker disease activity score could be used to track response to rituximab treatment in patients with rheumatoid arthritis, researchers report.

Source:

Arthritis Res Ther 2018; 20: 256

28-11-2018 | Rheumatoid arthritis | News

Equivalence of GP2015, etanercept demonstrated

Findings from the EQUIRA trial suggest that the etanercept biosimilar GP2015 has similar efficacy and safety profiles to its reference product.

27-11-2018 | Rheumatoid arthritis | News

News in brief

Lasting benefits of sirukumab demonstrated in RA patients

Follow-up results from the SIRROUND-D trial indicate that patients with rheumatoid arthritis refractory to DMARDs who are treated with sirukumab experience sustained improvements in clinical outcomes for up to 2 years.

26-11-2018 | Rheumatoid arthritis | Article

Chronic opioid use in rheumatoid arthritis: Prevalence and predictors

Lee YC. Arthritis Rheumatol 2018. doi: 10.1002/art.40789

21-11-2018 | Rheumatoid arthritis | News

ALC measurement sufficient to monitor infection risk in tofacitinib-treated RA

An evaluation of the temporal effects of tofacitinib on lymphocyte counts suggests that monitoring of absolute lymphocyte count alone is sufficient to minimize the risk for serious infection in patients with rheumatoid arthritis.

Source:

Arthritis Rheum 2018; doi:10.1002/art.40780

16-11-2018 | Rheumatoid arthritis | News

News in brief

Subcutaneous, intravenous tocilizumab similarly effective in RA

The subcutaneous and intravenous formulations of tocilizumab have comparable effectiveness, real-world study results suggest.

No worsening in disease activity with switch to biosimilar etanercept

Disease activity does not change following the switch from etanercept to the biosimilar formulation SB4, and treatment retention rates may be determined by patient-specific factors, suggests an analysis of the DANBIO registry.

15-11-2018 | Etanercept biosimilar | Highlight | News

No worsening in disease activity with switch to biosimilar etanercept

Disease activity does not change following the switch from etanercept to the biosimilar formulation SB4, and treatment retention rates may be determined by patient-specific factors, suggests an analysis of the DANBIO registry.

Source:

Ann Rheum Dis 2018; doi:10.1136/annrheumdis-2018-213474

Minimizing infection risk with biologic therapy

While the development of biologics has revolutionized treatment of rheumatic diseases, these agents can lead to immunosuppression and increased infection risk. Eoin Feeney discusses the role of screening and treatment for latent infection prior to therapy, vaccination timing, and travel risks in patients taking these medications.

14-11-2018 | Infection | Editorial | Article

Minimizing infection risk with biologic therapy

While the development of biologics has revolutionized treatment of rheumatic diseases, these agents can lead to immunosuppression and increased infection risk. Eoin Feeney discusses the role of screening and treatment for latent infection prior to therapy, vaccination timing, and travel risks in patients taking these medications.

Author:
Eoin Feeney

12-11-2018 | Rheumatoid arthritis | News

News in brief

Further support for 3-month assessment to guide DMARD adjustment in RA patients

Measuring disease activity at 3 months can help predict DMARD response at 6 months in patients with rheumatoid arthritis, researchers report.

image credits